Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 7 (2), 149-63

Update on the Cardiac Safety of Moxifloxacin

Comparative Study

Update on the Cardiac Safety of Moxifloxacin

Wilhelm Haverkamp et al. Curr Drug Saf.


Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in a large patient population from Phase II-IV randomized active-controlled clinical trials. Moxifloxacin 400 mg once-daily monotherapy was administered orally (PO) or sequentially (intravenous/oral, IV/PO). Across 64 trials, 21,298 patients received PO therapy (10,613 moxifloxacin, 10,685 comparators) while 6846 received sequential IV/PO therapy (3431 moxifloxacin, 3415 comparators). Treatment-emergent cardiac adverse event (AE) rates were similar for moxifloxacin and comparators in PO (6.6% vs 5.8%) and IV/PO (11.0% vs 12.0%) trials. Treatment-emergent cardiac adverse drug reactions were rare in PO (moxifloxacin 3.2% vs comparators 2.4%) and IV/PO (moxifloxacin 1.4% vs comparators 1.5%) patients. There were five (<0.02%) treatment-emergent drug-related deaths due to cardiac events out of 28,144 patients; one PO patient died treated with comparators, one patient died treated with IV/PO moxifloxacin, and three patients died after treatment with IV/PO comparators. Only one case of treatment-related non-fatal torsade de pointes occurred in the comparator arm. Incidence rates of cardiac AEs remained low in populations at elevated risk of cardiac events predisposed to QTc prolongation (i.e. community-acquired pneumonia patients admitted to the intensive care unit and/or mechanical ventilation, patients with documented prolongation of baseline QTc interval, women, and patients ≥ 65 years old). There was no evidence of unexpected cardiac events. After moxifloxacin treatment, an expected small prolongation in QTcB and QTcF was found. This analysis of numerous clinical trials shows the favorable cardiac safety profile of moxifloxacin, when used appropriately and according to its label, versus other antibiotics.


Fig. (1)
Fig. (1)
Patient Disposition Showing Numbers with Baseline and Post-Baseline ECG Data.
Fig. (2)
Fig. (2)
Boxplots for QTcB Intervals in Randomized Active-Controlled Phase II to IV Studies where ECG was Recorded at Baseline and Post baseline (PO) and Baseline, Day 1 and Day 3 (IV/PO) of Treatment with Moxifloxacin or Comparators.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles


    1. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol Clin Exp. 2008;23(Suppl 1):3–14. - PubMed
    1. Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care. 2007;13(7 Suppl):S178–88. - PubMed
    1. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219–33. - PubMed
    1. Salvi V, Karnad DR, Panicker GK, Kothari S. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol. 2010;159:34–48. - PMC - PubMed
    1. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83:481–8. - PubMed

Publication types

MeSH terms